…cell suppressive factors. Thus, Aim 3 will test in preclinical models our hypothesis that combining STAT3 inhibition with HER2-specific T cells will more effectively eradicate GBMs than T cells alone. …
…derived from CD34+ HSCs combined with HSC transplantation may provide enhanced anti-B-ALL-specific NK effectors with long-term persistence, thus likely increasing the efficacy of NK cell therapy for B-ALL. To test…
…to a much-anticipated cure for cancer. You can also stay informed about the latest news by signing up for our monthly email and other ACGT communications. Immune cells versus cancer…
…please sign up for our monthly email newsletter. This free resource provides you with the latest news about the field of cancer cell and gene therapy. What is oncolytic virus…
…communications to get the latest news delivered to your inbox. Page sources ‘Remote-controlled’ CAR-T cell therapy safer, more potent in Stanford mouse studies. Stanford Medicine. Retrieved from: https://med.stanford.edu/news/all-news/2022/05/snip-car-t-cell-therapy.html. Accessed: 06/08/2022….
…options.” Sign up for ACGT’s email communications list to get the latest news in cancer treatment and research, specifically about cancer cell and gene therapy. Page sources Exercise Amplifies Immune…
…to treat complex and challenging solid tumors. SIGN UP FOR MORE ADVANCEMENTS Page sources Implant Churns Out CAR-T Cells to Combat Cancer in Animal Models. UNC School of Medicine. Retrieved…
…glioblastoma, and the average survival is 8 months. It’s the most common primary brain tumor, has one of the poorest survival rates of any type of cancer, and is one…
…for all types of cancer. Subscribe to our free mailing list Transforming cancer treatment. Established approaches for treating cancer include surgery, chemotherapy and radiation therapy — all of which come…
…news and updates about cell and gene therapy research advancements. Sign up here to join and receive a free monthly email newsletter along with other free communications from ACGT. What…
…announced that the 5-year relapse-free survival rate was 44%. This means nearly half of patients had no signs of cancer for five years. Other stats of note are: 82% remission…
…for Cancer Gene Therapy as Content Manager in November 2021. “I feel this vision – a cancer-free future – is my calling,” says Mr. Golden, who earned a journalism degree…
Many of the people behind “Of Medicine and Miracles” gathered last month with director Ross Kauffman and producer Robin Honan to celebrate Emily Whitehead’s 10-year anniversary of being cancer-free. Photo…
…(BCH), ChainLink (LINK), Compound (COMP), Curve (CRV), Dai (DAI), Decentraland (MANA), Dogecoin (DOGE), Enjin Coin (ENJ), Fantom (FTM), Filecoin (FIL), Gemini Dollar (GUSD), Injective Protocol (INJ), Kyber Network (KNC), Litecoin…
…register to attend, please visit the Immuno-Oncology 360 page on the Conference Forum website. SIGN UP FOR ACGT’S EMAIL LIST Making potent CAR T cells to fight prostate cancer CAR…
NOTE: This page was updated 12/19/2022 with information regarding a new clinical study at Abramson Cancer Center testing the idea of a second CAR T-cell infusion for cancer patients. One…
…receiving Breyanzi. In a recent phase 2 clinical trial, 45% of CLL and SLL patients had an anti-tumor response after receiving Breyanzi and 18.4% had a complete response (no sign…
…protein receptor target for T-cell therapy. CAR T-cell therapy was tested on human and mouse models of melanoma (a skin cancer). Engineered T-cell receptor therapy was tested on human and…
…cancer – and the first for a solid tumor. Phase 3 clinical trial leads to approval The FDA approval comes on the heels of a Phase 3 trial using KIMMTRAK…
…T cells. HLA is part of the major histocompatibility complex (MHC), which includes fragments of proteins called peptides. When these peptides are from a cancerous protein, HLA presents them to…
